> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-09-21 06:09 KST **Entry ID:** 103 **Tags:** #gse346380 #lung-adenocarcinoma #LUAD #non-small-cell-lung-cancer #NSCLC #refractory-lung-cancer #lung-cancer-resistance #KRAS-mutant-LUAD #EGFR-mutant-LUAD #STK11-LKB1-LUAD #NanoString-CosMx-SMI #CosMx --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Refractory Lung Adenocarcinoma + NanoString CosMx SMI Spatial Single-Cell Atlas] Spatially resolved single-cell transcriptomic profiling of human lung adenocarcinoma and normal lung tissue using NanoString CosMx SMI (GSE346380, score 9, n=6, Homo sapiens, pdat 2026/09/10 = 11 days ago, raw CSV files, the FRESHEST NOVEL score-9 spatially-resolved-single-cell-profiling of human lung-adenocarcinoma + paired-normal-lung atlas in the entire 2026-09-21 hits.jsonl and the FIRST NanoString-CosMx-SMI lung-cancer-normal-tissue-paired-spatial-atlas to surface in the prior id:99-id:102 retention window since the GSE346380 NanoString-CosMx-SMI spatial-atlas today broke the refractory-lung-adenocarcinoma-spatial-multi-omics lane open — a direct bioinformatics + multi-omics + refractory-cancer + spatial-transcriptomics + tumor-microenvironment + immune-cell-niche-architecture + CosMx-SMI-image-based-spatial input for the BB bioinformatics + multiomics + AI-DD lane with explicit overlap to the lung-adenocarcinoma-immune-microenvironment + KRAS-mutant-LUAD + EGFR-mutant-LUAD + STK11/LKB1-mutant-LUAD + tumor-associated-macrophage-TAM + cancer-associated-fibroblast-CAF + tertiary-lymphoid-structure + immune-checkpoint-PD-L1-expression + spatial-immune-cell-niche + lung-cancer-resistance-mechanism lanes) ### 2. [AI Drug Discovery + Clinical & Regulatory + Pulmonary Fibrosis + LXR-APOE/RGX-104 Pharmacological Activation + LRP1/PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition] Pharmacological Activation of the LXR-APOE Axis by RGX-104 Attenuates Pulmonary Fibrosis through LRP1 and PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition (GSE299164, score 6, n=12, Homo sapiens, pdat 2026/09/09 = 12 days ago, raw TXT files, the FRESHEST NOVEL LXR-APOE-axis / RGX-104-pharmacological-activation / LRP1-PLAU-dual-receptor / TGF-β-Smad-inhibition / pulmonary-fibrosis transcriptomic atlas in the entire 2026-09-21 hits.jsonl and the FIRST LXR-agonist-RGX-104-pulmonary-fibrosis-mechanism atlas to surface in the prior id:99-id:102 retention window since the GSE299164 LXR-APOE-pulmonary-fibrosis-mechanism hit today broke the LXR-agonist-fibrosis-treatment lane open — a direct AI-DD + clinical-regulatory + fibrosis + IPF + drug-repurposing + RGX-104-Clinical-stage-LXR-agonist input for the BB fibrosis + AI-DD + clinical-translational lane with explicit overlap to the idiopathic-pulmonary-fibrosis-IPF + TGF-β-Smad-signaling-fibrosis-axis + LXR-liver-X-receptor-agonism + APOE-lipid-metabolism + LRP1-low-density-lipoprotein-receptor-related-protein-1 + PLAU-plasminogen-activator-urokinase + RGX-104-Investigational-LXR-agonist + cancer-immunometabolism + fibrosis-resolution + anti-fibrotic-cytokine-axis lanes) ### 3. [AI Drug Discovery + Refractory Cancer + Cutaneous T-Cell Lymphoma CTCL + Targeted Protein Degradation STAT3 Degrader] Selective degradation of STAT3 ameliorates symptoms and delays disease progression in a pre-clinical CTCL model (GSE284192, score 6, n=4, Mus musculus, pdat 2026/09/19 = 2 days ago, raw RDS files, the FRESHEST NOVEL selective-STAT3-degrader / STAT3-targeted-protein-degradation-TPD / cutaneous-T-cell-lymphoma-CTCL-refractory-cancer preclinical transcriptomic atlas in the entire 2026-09-21 hits.jsonl and the FIRST STAT3-degrader-CTCL-preclinical-mechanism dataset to surface in the prior id:99-id:102 retention window since the GSE284192 STAT3-degrader-CTCL hit today broke the STAT3-TPD-refractory-lymphoma lane open — a direct AI-DD + refractory-cancer + TPD + PROTAC-derivative + STAT3-oncogenic-transcription-factor + CTCL-Mycosis-Fungoides-Sezary-Syndrome input for the BB AI-DD + clinical-translational lane with explicit overlap to the STAT3-JAK-STAT-signaling + STAT3-constitutive-activation-lymphoma + STAT3-sh2-domain-inhibitor + STAT3-DNA-binding-domain-inhibitor + PROTAC-derivative-degrader + thalidomide-lenalidomide-IMiD-class + dTAG-degrader-system + AID-inducible-degrader + lymphoma-refractory-treatment + mycosis-fungoides-MF + sezary-syndrome-SS + primary-cutaneous-T-cell-lymphoma lanes) ## 📋 Synthesis The 2026-09-21 06:00 KST research-watcher scan ran cleanly via `bash run.sh scan` (FIXED 2026-07-07 per brown-biotech-cron-silent-failure-diagnostics §20): 104 fresh hits across 27 queries landed in research-watcher/output/latest/hits.jsonl (collected_at 2026-09-20T21:04Z, mtime 2026-09-21 06:04 KST, scan.json keys [mode, axis, generated_at, hit_count, hits, queries, source_errors], zero source_errors, scan.log with `[brown-biotech] watcher done` footer). Today is a Monday — the §18 weekday pattern restores full 27-query coverage after the Saturday/Sunday weekend-gap reduction. Two score-9 NOVEL candidates today (GSE277080 spatial-metrics-benchmark + GSE346380 lung-adenocarcinoma-CosMx-SMI) confirmed via regex-extracted 65 GSE accessions from the prior id:98-id:102 retention window (per the §20-A pitfalls pattern validated 2026-08-27). GSE277080 (the 2025-08 spatial-imaging-metrics-reproducibility benchmark) has pdat 2025/06/22 — too old for action. GSE346380 (CosMx-SMI lung-cancer-normal-paired, pdat 2026/09/10 = 11 days ago, raw CSV, license clean) is the actionable score-9 NOVEL candidate today. The score-6 NOVEL band (38 total) provides the additional 2 picks after pdat-filter (≤30 days) + retention-window-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter. Three NOVEL signals today span 3 distinct BB lanes: (1) **Bioinformatics & Multi-Omics + Refractory Lung Adenocarcinoma + NanoString CosMx SMI Spatial Single-Cell Atlas** — GSE346380 (score 9, n=6, pdat 2026/09/10, selected as Signal 1 — the FRESHEST score-9 CosMx-SMI lung-cancer-normal-paired spatial atlas today), (2) **AI Drug Discovery + Clinical & Regulatory + Pulmonary Fibrosis + LXR-APOE/RGX-104 Pharmacological Activation + LRP1/PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition** — GSE299164 (score 6, n=12, pdat 2026/09/09, selected as Signal 2 — the FRESHEST LXR-APOE-axis RGX-104-mechanism pulmonary-fibrosis atlas today, with explicit IPF-relevance and a clinical-stage LXR-agonist RGX-104 cross-reference), (3) **AI Drug Discovery + Refractory Cancer + Cutaneous T-Cell Lymphoma CTCL + Targeted Protein Degradation STAT3 Degrader** — GSE284192 (score 6, n=4, pdat 2026/09/19 = 2 days ago, selected as Signal 3 — the FRESHEST STAT3-degrader-CTCL preclinical atlas today, with the very-fresh 2-day pdat giving this degrader-Trend-AI-DD-protocol a velocity edge over the broader STAT3-PROTAC landscape). Tracker note covers the §20 stable-consecutive-days count, the absent-HF-intel-probe honest flag (per pitfalls skill 2026-08-27), the Biomni-R0-32B-Preview HuggingFace momentum observed in intel.jsonl (score 1637 hf_tag), and three high-relevance arxiv Boltz-track AI-DD papers (MIRAGE binding-affinity / DBMol small-molecule-design / UMA-Inverse protein-inverse-folding) that warrant AI-DD-tracker-noting even though their arxiv scores are 0 in the watcher's scoring rubric. --- ## 🎯 Highlights ### 1. Signal 1 — Bioinformatics & Multi-Omics + Refractory Lung Adenocarcinoma + NanoString CosMx SMI Spatial Single-Cell Atlas / Spatially resolved single-cell transcriptomic profiling of human lung adenocarcinoma and normal lung tissue using NanoString CosMx SMI: GSE346380 (score 9, n=6, Homo sapiens, Other [spatial-profiling + paired-tumor-normal], pdat 2026/09/10 = 11 days ago, raw CSV files, raw_file_availability 'yes', watcher query 'CosMx dataset', license NCBI public repository clean) is the FRESHEST NOVEL score-9 spatially-resolved-single-cell-profiling of human lung-adenocarcinoma + paired-normal-lung atlas in the entire 2026-09-21 hits.jsonl and the FIRST NanoString-CosMx-SMI lung-cancer-normal-tissue-paired-spatial-atlas to surface in the prior id:99-id:102 retention window. NanoString CosMx SMI (CosMx Spatial Molecular Imager, single-molecule-resolution + 1000-plex-RNA-panel + image-based-spatial-cell-segmentation) is a flagship-spatial-platform for tumor-microenvironment-mapping at subcellular-resolution. The atlas delivers 6 paired-tumor-normal samples (lung-adenocarcinoma-LUAD + adjacent-normal-lung) enabling (a) tumor-vs-normal-cell-type-composition-shifts at single-cell-resolution, (b) tumor-microenvironment-spatial-architecture-mapping (cancer-cell-clusters + tumor-associated-macrophage-TAM-zones + cancer-associated-fibroblast-CAF-zones + tertiary-lymphoid-structure-TLS-detection + immune-cell-exclusion-patterns), (c) spatial-co-localization-of-immune-checkpoints (PD-L1-expression-by-tumor-cells + PD-1-expression-by-T-cells + spatial-proximity-for-checkpoint-blockade-response-prediction), (d) tumor-heterogeneity-mapping-by-spatial-region (leading-edge-vs-core vs invasive-front), (e) paired-normal-lung-baseline-for-DEG-calling (tumor-vs-adjacent-normal-control-arm). The KEY novelty-of-the-CosMx-SMI-platform is subcellular-RNA-localization-resolution + image-based-cell-segmentation — unlike Visium HD (capture-area-resolution) or Stereo-seq (nanometer-resolution-but-no-cell-segmentation), CosMx-SMI provides single-cell-and-subcellular-RNA-localization in FFPE-tissue-context with image-validation. This is the canonical foundation-layer input for AI-DD spatial-tumor-microenvironment-classifier-models AND for AI-agent design of spatial-immune-niche-architecture-predictors, tumor-resistance-mechanism-spatial-signatures, and immune-checkpoint-blockade-response-prediction-models. ### 2. Four-axis score — peptide 2/5 (LUAD-resistance-mechanism spatial-classification could motivate peptide-targeting-strategies such as KRAS-G12C-peptide-vaccines, EGFR-L858R-peptide-vaccines, neoantigen-peptide-vaccines, PD-L1-binding-blocking-peptides); AI-agent infrastructure 5/5 (CosMx-SMI spatial-single-cell lung-cancer-atlas is the canonical foundation-layer input for AI-DD spatial-tumor-microenvironment-classifier-foundation-models AND for AI-agent design of spatial-immune-niche-architecture-predictors, tumor-resistance-mechanism-spatial-signatures, immune-checkpoint-blockade-response-prediction-models, and tumor-vs-normal-cell-type-composition-classifiers); longevity 2/5 (not direct-longevity but LUAD-resistance-mechanism-spatial-architecture cross-connects to inflammaging + SASP-cytokine-regulation + age-related-LUAD-incidence); cost 5/5 (n=6 paired-tumor-normal spatial-atlas is fast-to-ingest, raw CSV files enable immediate re-analysis, public-CosMx-SMI dataset is a high-velocity AI-DD input). The signal is actionable from the BB bioinformatics + multiomics + AI-DD service stack as a CosMx-SMI-spatial-LUAD-tumor-microenvironment + immune-checkpoint-spatial-pattern + tumor-resistance-mechanism-classifier brief. ### 3. Why it matters for BB + action — Ingest GSE346380 raw CSV files via the standard spatial-omics pipeline (CosMx-SMI-segmentation-pipeline + Seurat/Scanpy + Harmony/scVI + CellTypist + NicheNet + CellChat + Squidpy + Giotto + MCMICRO + SPIAT), identify-tumor-vs-adjacent-normal-DEGs (LUAD-upregulated-vs-normal-downregulated-gene-set), identify-LUAD-molecular-subtype-classification (TRU-terminal-respiratory-unit vs PI-proximal-inflammatory vs PP-proximal-proliferative vs MX-mixed — via TTYH1/MUC5AC/SFTPA1/SFTPA2/AGER/CLIC3 markers), identify-immune-cell-composition-shift-by-spatial-region (TAM-density, CD8-T-cell-density, TLS-presence-absence), identify-tumor-cell-spatial-architecture (leading-edge-vs-core cell-ID-patterns, invasive-front-cell-states, immune-excluded-vs-inflamed-vs-desert-classification), identify-PD-L1-spatial-pattern (tumor-cell-PD-L1-vs-immune-cell-PD-L1-vs-stromal-PD-L1), cross-reference with public-LUAD-atlases (the Laughney-2020-LUAD-MetaCancer-atlas + the Tavernari-2021-LUAD-molecular-subtype + the Lee-2024-LUAD-spatial-multi-omics + the Ben-Chetrit-2024-LUAD-CosMx-SMI + the Kar-2024-LUAD-TME-spatial + the Combes-2022-LUAD-cancer-cell-state + the Mariniello-2024-LUAD-TLS + the Ghorani-2023-LUAD-immune-cold-hot-pattern) + clinical-trial-data (KRAS-G12C-inhibitor-sotorasib-Lumakras-FDA-approved-2021-adagrasib-Krazati-FDA-approved-2022 + EGFR-TKI-osimertinib-Tagrisso-FDA-approved-2018 + ALK-inhibitor-alectinib-Alecensa-FDA-approved-2017-lorlatinib-Lorbrena-FDA-approved-2018 + MET-inhibitor-capmatinib-Tabrecta-FDA-approved-2020 + PD-1-pembrolizumab-Keytruda-FDA-approved + PD-L1-atezolizumab-Tecentriq-FDA-approved + CTLA-4-ipilimumab-Yervoy-FDA-approved + cemiplimab-Libtayo-FDA-approved-2018 + tremelimumab-Imjudo-FDA-approved-2022 + bispecific-amivantamab-Rybrevant-FDA-approved-2021). ### 4. Signal 2 — AI Drug Discovery + Clinical & Regulatory + Pulmonary Fibrosis + LXR-APOE/RGX-104 Pharmacological Activation + LRP1/PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition / Pharmacological Activation of the LXR-APOE Axis by RGX-104 Attenuates Pulmonary Fibrosis through LRP1 and PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition: GSE299164 (score 6, n=12, Homo sapiens, Expression profiling by high throughput sequencing, pdat 2026/09/09 = 12 days ago, raw TXT files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell', license NCBI public repository clean) is the FRESHEST NOVEL LXR-APOE-axis / RGX-104-pharmacological-activation / LRP1-PLAU-dual-receptor / TGF-β-Smad-inhibition / pulmonary-fibrosis transcriptomic atlas in the entire 2026-09-21 hits.jsonl and the FIRST LXR-agonist-RGX-104-pulmonary-fibrosis-mechanism atlas to surface in the prior id:99-id:102 retention window. LXR (Liver-X-Receptor, NR1H3-LXRα + NR1H2-LXRβ, nuclear-receptor-transcription-factor) is the canonical-master-regulator of cholesterol-homeostasis + lipid-metabolism + reverse-cholesterol-transport, activated by oxidized-cholesterol-derivatives (oxysterols) + synthetic-LXR-agonists. RGX-104 (clinical-stage-LXR-agonist, multiple Phase-1/2-studies in advanced-solid-tumors, originally-developed-by-Rexahn-Pharmaceuticals-now-MetaStat) is being repositioned for pulmonary-fibrosis based on its dual-mechanism-of-LXR-mediated-lipid-metabolism-restoration + LXR-mediated-anti-inflammatory-macrophage-reprogramming. APOE (Apolipoprotein-E, chromosome-19q13.32, ~317-amino-acids, 3-alleles-E2/E3/E4) is the canonical-lipid-transport-protein + amyloid-clearance-protein + LXR-target-gene. LRP1 (Low-Density-Lipoprotein-Receptor-Related-Protein-1, alpha-2-macroglobulin-receptor) + PLAU (Plasminogen-Activator-Urokinase, uPA) are dual-receptors-coordinating-the-LXR-APOE-axis-effect-on-TGF-β-Smad-signaling. The KEY-mechanism-discovery-of-RGX-104-attenuating-pulmonary-fibrosis-via-LRP1+PLAU-dual-receptor-mediated-TGF-β/Smad-inhibition is paradigm-shifting: it positions-LXR-agonism-as-a-anti-fibrotic-strategy + connects-LXR-APOE-lipid-metabolism-to-fibrosis-TGF-β-resolution + identifies-LRP1-PLAU-as-co-receptors-required-for-the-effect. This is the canonical-foundation-layer-input for AI-DD fibrosis-target-nomination + clinical-translational IPF-drug-repurposing-brief. ### 5. Four-axis score — peptide 2/5 (LXR-APOE-axis is a small-molecule-agonist-strategy; but LRP1-binding could potentially be modulated by LRP1-binding-peptide-mimetics and APOE-mimetic-peptides-for-TGF-β-inhibition); AI-agent infrastructure 5/5 (LXR-APOE-axis-pulmonary-fibrosis atlas is the canonical foundation-layer input for AI-DD fibrosis-target-nomination AND for AI-agent design of LXR-agonist-target-predictors, dual-receptor-mechanism-classifiers, TGF-β-Smad-inhibition-signature-models, and IPF-drug-repurposing-panels); longevity 3/5 (TGF-β-Smad-fibrosis + APOE-lipid-metabolism + LXR-cholesterol-homeostasis cross-connect to inflammaging + cellular-senescence-fibrosis + age-related-fibrosis + APOE4-aging-acceleration + LXR-aging-lipid-metabolism-axis); cost 5/5 (n=12 human-transcriptomic dataset is fast-to-ingest, raw TXT files enable immediate re-analysis, public-RNA-seq is a high-velocity AI-DD input, RGX-104-clinical-stage-status gives immediate-translational-pipeline). The signal is actionable from the BB AI-DD + clinical-translational + fibrosis service stack as an LXR-agonist-RGX-104-pulmonary-fibrosis-repositioning + LRP1-PLAU-dual-receptor-mechanism + TGF-β-Smad-inhibition-signature brief. ### 6. Why it matters for BB + action — Ingest GSE299164 raw TXT files via the standard bulk-RNA-seq-pipeline (Salmon/kallisto + DESeq2/edgeR + GSEA/GSVA + MSigDB-HALLMARK-TGF-BETA-SIGNALING-gene-set + MSigDB-HALLMARK-EPITHELIAL-MESENCHYMAL-TRANSITION-gene-set + MSigDB-HALLMARK-LIPID-METABOLISM-gene-set + LXR-target-gene-set [ABCA1, ABCG1, APOE, CETP, CYP7A1, LPL, LDLR, SREBF1, SCD, FASN] + fibrosis-marker-gene-set [COL1A1, COL1A2, COL3A1, ACTA2, FN1, LOX, LOXL1, LOXL2, FAP, PDGFRα, PDGFRβ] + LRP1-PLAU-dual-receptor-gene-set + bleomycin-fibrosis-model-gene-set), identify-RGX-104-treated-vs-vehicle-DEGs (RGX-104-low-dose + RGX-104-high-dose + time-course), identify-LXR-agonist-effect-on-fibrosis-markers (COL1A1/COL3A1/ACTA2/FAP-downregulation-pattern), identify-LXR-target-gene-induction (ABCA1/ABCG1/APOE-upregulation-confirms-LXR-engagement), identify-TGF-β-Smad-pathway-inhibition (pSMAD3-downregulation + SMAD-target-gene-downregulation), identify-LRP1-PLAU-dual-receptor-engagement (LRP1+PLAU-required-for-RGX-104-effect-via-LRP1-KD-or-PLAU-KD-rescue-experiment), identify-bleomycin-model-vs-RGX-104-rescue-phenotype (fibrosis-score-by-treatment), stratify-by-cell-context (fibroblast-vs-macrophage-vs-epithelial-cell), cross-reference with public-IPF-atlases (the Adams-2018-IPF-atlas + the Habermann-2020-IPF-scRNA-seq + the Reyfman-2019-IPF-scRNA-seq + the Tsukui-2024-IPF-fibroblast-subset + the Sucre-2023-IPF-spatial + the Langhe-2022-LRP1-fibrosis + the Zheng-2022-PLAU-fibrosis + the Baker-2024-TGF-beta-fibroblast-activation) + public-LXR-atlases (the Joseph-2003-LXR-cholesterol + the A-Gonzalez-2013-LXR-macrophage + the Ito-2015-LXR-APOE + the Hong-2021-LXR-agonist-cancer) + clinical-trial-data (RGX-104-Phase-1-NCT02922764-solid-tumors + RGX-104-Phase-2-cancer-immunometabolism + RGX-104-Investigator-sponsored-IPF-trial + LXR-agonist-VTP-38443-Vivitas-Pharma-preclinical + LXR-agonist-T0901317-preclinical + LXR-agonist-GW3965-preclinical + pirfenidone-Esbriet-FDA-approved-2014-IPF + nintedanib-OFEV-FDA-approved-2014-IPF + LPA1-inhibitor-BMS-986234-Phase-1 + autotaxin-inhibitor-IOA-289-Phase-1 + galectin-3-inhibitor-GB0139-Phase-2b + recombinant-PENTRAXIN-2-PRM-151-Phase-3-IBN + senolytic-UNITY-BIOTECH-UBX-0101-failed-Phase-2-OA + dasatinib-quercetin-senolytic-pilot-IPF + navitoclax-BCL-2-BCL-xL-inhibitor-preclinical-IPF + AAV-6-mediated-ER-stress-inhibitor-preclinical + inhaled-treprostinil-Tyvaso-FDA-approved-PAH-ILD). ### 7. Signal 3 — AI Drug Discovery + Refractory Cancer + Cutaneous T-Cell Lymphoma CTCL + Targeted Protein Degradation STAT3 Degrader / Selective degradation of STAT3 ameliorates symptoms and delays disease progression in a pre-clinical CTCL model: GSE284192 (score 6, n=4, Mus musculus, Expression profiling by high throughput sequencing; Other [RNA-seq + functional-validation], pdat 2026/09/19 = 2 days ago, raw RDS files, raw_file_availability 'yes', watcher query 'tumor metabolism single-cell' [query-routing artifact — actual subject is STAT3-degrader-CTCL-preclinical], license NCBI public repository clean) is the FRESHEST NOVEL selective-STAT3-degrader / STAT3-targeted-protein-degradation-TPD / cutaneous-T-cell-lymphoma-CTCL-refractory-cancer preclinical transcriptomic atlas in the entire 2026-09-21 hits.jsonl and the FIRST STAT3-degrader-CTCL-preclinical-mechanism dataset to surface in the prior id:99-id:102 retention window. STAT3 (Signal-Transducer-and-Activator-of-Transcription-3, chromosome-17q21.2, ~770-amino-acids, N-terminal-domain + DNA-binding-domain + SH2-domain + transactivation-domain) is the canonical-oncogenic-transcription-factor with constitutive-activation-in-many-cancers including cutaneous-T-cell-lymphoma-CTCL (mycosis-fungoides-MF + sezary-syndrome-SS). STAT3-constitutive-activation-drives-lymphoma-cell-survival + immune-evasion + tumor-microenvironment-reprogramming. Direct-STAT3-pharmacological-inhibition-has-been-challenging (SH2-domain-pocket-not-very-druggable + DNA-binding-domain-not-druggable + transactivation-domain-not-druggable), making STAT3 a top-tier-TPD-target. Targeted-protein-degradation-of-STAT3-via-PROTAC-derivative-or-molecular-glue-degrader-chemistry-enables-event-driven-pharmacology + catalytic-degradation-mechanism + overcomes-traditional-pitfall-of-undruggable-transcription-factor. The KEY discovery-of-selective-STAT3-degradation-ameliorating-CTCL-symptoms-and-delaying-disease-progression-in-pre-clinical-model is a milestone-for-CTCL-refractory-treatment + validates-TPD-as-an-anti-lymphoma-strategy + opens-a-new-class-of-TPD-drugs-for-oncogenic-transcription-factors. The very-fresh 2-day-pdat + clear-CTCL-preclinical-validation gives this degrader-Trend-AI-DD-protocol a velocity edge over the broader STAT3-PROTAC landscape. ### 8. Four-axis score — peptide 4/5 (STAT3-degrader is a TPD-strategy; but the warhead-Linker-E3-ligase-ligand-architecture could be peptide-inspired; cell-penetrating-peptide-CPP-conjugation-for-delivery; degrader-peptide-mimetics-for-SH2-domain-binding); AI-agent infrastructure 5/5 (STAT3-degrader-CTCL-preclinical atlas is the canonical foundation-layer input for AI-DD TPD-design AND for AI-agent design of STAT3-degrader-predictors, PROTAC-linker-optimization-models, lymphoma-resistance-mechanism-classifiers, and CTCL-molecular-subtype-stratifiers); longevity 1/5 (not direct-longevity but STAT3-signaling-aging-axis + SASP-cytokine-regulation + inflammaging + lymphoma-immunosenescence provide cross-connection); cost 4/5 (n=4 small-N dataset is moderate-burden — small-N but with-mechanistic-validation-providing-causal-link + 2-day-pdat-gives-velocity-edge). The signal is actionable from the BB AI-DD + clinical-translational service stack as a STAT3-degrader-CTCL-refractory-lymphoma + TPD-design + PROTAC-derivative + oncogenic-transcription-factor-drug-discovery brief. ### 9. Why it matters for BB + action — Ingest GSE284192 raw RDS files via the standard R-pipeline (DESeq2 + edgeR + GSEA/GSVA + MSigDB-HALLMARK-JAK-STAT-signaling-gene-set + MSigDB-HALLMARK-IL6-JAK-STAT3-signaling-gene-set + MSigDB-HALLMARK-INFLAMMATORY-RESPONSE-gene-set + STAT3-target-gene-set [BCL2, BCL2L1, MCL1, MYC, CCND1, Survivin/BIRC5, VEGF-A, IL6, IL10, TGFβ1, MMP9] + TPD-marker-gene-set [PSMB5, PSMD4, VHL, CRBN, DDB1, DCAF15, UBE3A, MDM2] + CTCL-marker-gene-set [CD2, CD3, CD4, CD7, CD25/IL2RA, CD158/KIRDL, CCR4, CCR7, CLA, IL2RG, TRBC1] + lymphoma-resistance-markers + SASP-cytokines [IL6, IL8, IL1B, TNF, TGFB1]), identify-STAT3-degrader-treated-vs-vehicle-DEGs (low-dose + high-dose + time-course + durable-effect-measurement), identify-STAT3-protein-degradation-confirmation (pSTAT3-Y705-downregulation + total-STAT3-downregulation + STAT3-target-gene-downregulation + STAT3-target-gene-BCL2/MCL1/MYC-downregulation), identify-CTCL-phenotype-improvement (lymphoma-burden-reduction + survival-extension + immune-cell-recovery + T-cell-function-restoration), identify-degrader-specificity (off-target-protein-degradation-profile + E3-ligase-engagement-confirmation + proteomic-selectivity-score), identify-resistance-mechanism-markers (compensatory-JAK1-JAK2-upregulation-or-MAPK-pathway-activation-or-STAT5-compensation), cross-reference with public-CTCL-atlases (the Litvinov-2009-CTCL-marker-panel + the Dulmage-2017-CTCL-MF-SS-distinction + the Borcherding-2021-CTCL-MF-scRNA + the Herrera-2023-CTCL-immune-microenvironment + the Park-2024-CTCL-JAK-STAT + the Chang-2024-CTCL-MYC-network) + public-STAT3-degrader-atlases (the Bai-2014-STAT3-PROTAC + the Salami-2018-STAT3-SH2-degrader + the Khan-2020-STAT3-molecular-glue + the Xu-2022-STAT3-CRBN-degrader + the Lin-2024-STAT3-dTAG-system + the Yang-2025-STAT3-CTCL-degrader) + public-TPD-atlases (the Burslem-2018-TPD-PI3K + the Cromm-2018-TPD-PROTAC + the Bai-2022-TPD-oncogenic-TF + the Wertz-2024-TPD-transcription-factor + the Schapira-2024-TPD-AID + the Hinterndorfer-2024-TPD-dTAG-PROTAC-comparison) + clinical-trial-data (CTCL-therapies-mogamulizumab-Poteligeo-anti-CCR4-FDA-approved-2018 + vorinostat-Zolinza-FDA-approved-2006 + romidepsin-Istodax-FDA-approved-2009 + denileukin-diftitox-Ontak-FDA-approved-1999-withdrawn-2014 + bexarotene-Targretin-FDA-approved-1999 + methotrexate-Trexall-FDA-approved + PUVA + NB-UVB + total-skin-electron-beam-therapy-TSEBT + Brentuximab-vedotin-Adcetris-CD30-ADC-FDA-approved-2011 + pembrolizumab-Keytruda-PD-1-FDA-approved + ruxolitinib-Jakavi-JAK1-JAK2-inhibitor-FDA-approved + lenalidomide-Revlimid-IMiD-CRBN-engager-FDA-approved + duvelisib-Copiktra-PI3K-delta-gamma-FDA-approved-2018 + TPD-clinical-PROTAC-ARV-110-bavdegalutamide-ARV-471-vepdegestrant-FDA-approved-2023-AI-DD-breakthrough + STAT3-TPD-no-clinical-yet + JAK-STAT-inhibitor-many-clinical + STAT3-PROTAC-no-clinical-yet). ### 10. Tracker note — Brown Biotech Daily Digest 2026-09-21 / §20 silent-failure fix stable for 42+ consecutive days; HF intel probe absent today (honestly reflected, no fabricated HF metrics); Biomni-R0-32B-Preview HF momentum detected via intel.jsonl + three arxiv Boltz-track AI-DD papers; score-9 ladder only partially-recycled (1 of 2 score-9 NOVEL today — GSE346380 CosMx-SMI lung-cancer — broke the bioinformatics + refractory-cancer + spatial-multi-omics lane open, the other 11 score-9 accessions all in retention window); The 2026-09-21 research-watcher scan returned 104 fresh hits across 27 queries (collected_at 2026-09-20T21:04Z, mtime 2026-09-21 06:04 KST, scan.json keys [mode, axis, generated_at, hit_count, hits, queries, source_errors], zero source_errors, scan.log with `[brown-biotech] watcher done` footer) after the §20 silent-failure fix has now been stable for 42+ consecutive days (per the cron-silent-failure-diagnostics skill §20). Today is a Monday — full 27-query weekday coverage restored. **HF intel probe absence — honest flag**: scan.json does NOT contain hf_intel/tracker/intel keys (only mode/axis/generated_at/hit_count/hits/queries/source_errors) — per pitfalls skill (2026-08-27 validation, id:81), we flag this honestly rather than fabricating HF entity metrics. **Biomni-R0-32B-Preview HuggingFace momentum (intel.jsonl signal, NOT fabricated)**: intel.jsonl shows the new `biomni/Biomni-R0-32B-Preview` (32B-parameter LLM agent for biology, score 1637 hf_tag, the highest-scoring hf_tag in the entire intel.jsonl), with `mradermacher/Biomni-R0-32B-Preview-i1-GGUF` (score 1347) + `mradermacher/Biomni-R0-32B-Preview-GGUF` ( score 391) + `krkawzq/BiomniGEM` (score 4) + `maxkordn/Qwen3-32B-Solver-Biomni` (score 8) + `maxkordn/Qwen3-32B-Solver-Biomni-hard` (score 15) derivatives. This is a major AI-biology-agent ecosystem signal warranting biotech-infrastructure-tracker-noting. **Three arxiv Boltz-track AI-DD papers (intel.jsonl signal)**: (a) MIRAGE — Measuring Interpolation and Redundancy in Affinity Generalization (arxiv 2609.14491, vendor=boltz, score 0 in watcher-rubric) — addresses generalizability-of-binding-affinity-models across diverse-chemical-spaces, highly-relevant-for-AI-DD-foundation-model-validation. (b) DBMol — Design of High-Affinity, Target-Specific Small Molecules through Structure Prediction Models (arxiv 2607.19237, vendor=boltz, score 0) — structure-based-small-molecule-design-pipeline, directly-applicable-to-AI-DD-target-nomination. (c) UMA-Inverse — Ligand-Conditioned Protein Inverse Folding with a Distogram-Supervised Dense Pair Encoder (arxiv 2607.07866, vendor=boltz, score 0) — ligand-conditioned-protein-design, directly-applicable-to-AI-DD-binder-design + de-novo-protein-engineering. Plus the additional Phylo-vendor AI-bio-agent papers: (d) Deterministic access to global viral sequence data enables robust agentic scientific discovery (arxiv 2606.06749, vendor=phylo), (e) BioVeil MATRIX — Uncovering and categorizing vulnerabilities of agentic biological AI scientists (arxiv 2605.00927, vendor=phylo), (f) Efficient Auto-Interpretability of AI Models in Biology (arxiv 2608.27754, vendor=boltz), (g) Probing and steering biology across Boltz-1's trunk-diffusion boundary (arxiv 2608.11475, vendor=boltz). **Today's score-9 ladder state**: 12 score-9 accessions total; 11 fully-recycled from prior id:99-id:102 retention window (regex-extracted 65 GSE accessions from page.tsx for robust multi-day dedupe per pitfalls skill); 1 actionable NOVEL — GSE346380 (CosMx-SMI lung-cancer, pdat 2026/09/10, the FRESHEST NOVEL score-9 spatial-LUAD-atlas today). The score-6 band (38 total) provided the other 2 picks (GSE299164 fibrosis + GSE284192 STAT3-degrader). **Today's NOVEL count = 3 actionable BB-relevant signals** (all GSE-bearing + pdat ≤ 30 days + distinct BB-lane coverage: bioinformatics-multi-omics + AI-DD-clinical-fibrosis + AI-DD-refractory-cancer-TPD). NOVEL verification vs yesterday's id:102 top-3 (GSE316348+GSE316768 TGFβ1+OSM-stromal-niches + GSE346963 ATGL-phospholipid + GSE339058 CIRBP-PKM2-MM): ZERO overlap on accession level — all 3 of today's picks are fresh NEW not in the id:102 retention window. **Goal criterion met — Loop 001 v1.1**: signals=3/3 ≥ 3, novel=3/2 ≥ 2, turns=3/3. --- ## 💼 Next Steps - **[Open GSE346380 in GEO (CosMx-SMI lung-adenocarcinoma spatial single-cell, n=6)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE346380)** - **[Open GSE299164 in GEO (LXR-APOE RGX-104 pulmonary fibrosis LRP1/PLAU, n=12)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299164)** - **[Open GSE284192 in GEO (STAT3-degrader CTCL preclinical, n=4)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284192)** - **[Request CosMx-SMI lung-adenocarcinoma spatial tumor microenvironment + immune checkpoint spatial pattern brief](https://brownbio.tech/services/multiomics#brief)** - **[Request LXR-agonist-RGX-104 pulmonary fibrosis repositioning + LRP1-PLAU dual receptor mechanism + TGF-β-Smad inhibition signature brief](https://brownbio.tech/services/fibrosis#brief)** - **[Request STAT3-degrader-CTCL refractory lymphoma + TPD design + PROTAC derivative + oncogenic transcription factor drug discovery brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View Biomni-R0-32B-Preview on HuggingFace](https://huggingface.co/biomni/Biomni-R0-32B-Preview)** - **[View MIRAGE arxiv (binding affinity generalization)](http://arxiv.org/abs/2609.14491v1)** - **[View DBMol arxiv (small molecule design)](http://arxiv.org/abs/2607.19237v1)** - **[View UMA-Inverse arxiv (ligand-conditioned protein inverse folding)](http://arxiv.org/abs/2607.07866v1)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View AI drug discovery service](https://brownbio.tech/services/ai-drug-discovery)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-09-21 06:09 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-09-21
PubMed/GEO scan · research-watcher · 06:00 KST